10-QHealthcare

Boston Scientific Corporation

BSX · Period ending 2026-09-30 · Filed 2026-11-02 · Updated

In short

Boston Scientific Corporation (BSX) has revenue up 19.9% to $20.1B and net income up 56.7% to $2.9B year on year. Its net margin is 14.4% and gross margin 69.0%, and it trades at 19.3× trailing earnings. Fisclear flags 1 medium-severity risk and no high-severity ones. How we calculate this

Compare: BSX vs MDT · ABT vs BSX · BSX vs SYK · BSX vs ZBH

Valuation

Healthcare
Live · Yahoo Finance

Price

$41.98

P/E (TTM)

17.7x

Price ÷ earnings per share

P/B

2.4x

Price ÷ book value

P/S (TTM)

2.9x

Price ÷ revenue per share

Beta

0.58

Moderate market correlation

PEG Ratio

0.7x

P/E ÷ earnings growth rate

52-Week Range

$39.57$41.98 now$101.91

Decision Context

Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

BSX vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.2%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — BSX

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Net Income: $2.9B (+56.7% YoY) — Profit grew 57% — the company kept more of each dollar earned.

  • EPS (Diluted): $1.94 (+55.2% YoY) — Earnings per share rose 55% — each share earned more.

  • Operating Cash Flow: $4.5B (+32.0% YoY) — Operating cash flow grew 32% — the business generated more cash from day-to-day operations.

  • Gross Profit: $13.9B (+20.6% YoY) — Gross profit rose 21% — the spread between revenue and direct costs improved.

  • Revenue: $20.1B (+19.9% YoY) — Revenue grew 20% — the company sold more goods or services than the prior year.

◈

Weaknesses

No material weaknesses flagged.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Stock is within 10% of its 52-week low (39.57) — the market may be pricing in significant risk or sector weakness.

Year-over-Year Changes

Net Income

$2.9B

was $1.8B

+56.7%

Profit grew 57% — the company kept more of each dollar earned.

EPS (Diluted)

$1.94

was $1.25

+55.2%

Earnings per share rose 55% — each share earned more.

Operating Cash Flow

$4.5B

was $3.4B

+32.0%

Operating cash flow grew 32% — the business generated more cash from day-to-day operations.

Gross Profit

$13.9B

was $11.5B

+20.6%

Gross profit rose 21% — the spread between revenue and direct costs improved.

Revenue

$20.1B

was $16.7B

+19.9%

Revenue grew 20% — the company sold more goods or services than the prior year.

Risk Flags

0 high · 1 medium · 0 low
  • ◈ Medium

    Stock is within 10% of its 52-week low (39.57) — the market may be pricing in significant risk or sector weakness.

Technical Signals

Daily closes · 1-year data

Boston Scientific Corporation: common questions

Is Boston Scientific Corporation profitable?

Yes. Boston Scientific Corporation made a net profit of $2.9B in its latest fiscal year (fiscal 2025), a net margin of 14.4%.

Is Boston Scientific Corporation's revenue growing?

Yes. Revenue grew 19.9% year on year, to $20.1B.

What is Boston Scientific Corporation's P/E ratio?

Boston Scientific Corporation trades at 17.7× its trailing twelve-month earnings. In other words, the share price is about 18 times the profit per share the company earned over the past year.

Does Boston Scientific Corporation pay a dividend?

No dividend is currently expected from Boston Scientific Corporation, according to the latest market data.

What are the main risks for Boston Scientific Corporation?

Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Stock is within 10% of its 52-week low (39.57) — the market may be pricing in significant risk or sector weakness.

Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — BSX

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade BSX

Links open broker research pages. Not an endorsement or recommendation.

Research Boston Scientific Corporation

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.